Role of Antificolin II Antibody in Lupus Nephritis

Abstract

ystemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that may affect multiple organs and systems. It can be diagnosed based on a combination of clinical findings and laboratory work. Lupus nephritis is one of the most serious complications of SLE. As part of innate immunity, complement system plays a dual role in pathogenesis of SLE. The aim of this study was to assess the role of antificolin-2 as a marker to LN and its possible relationship to LN different classes. The present study is a case control study conducted on 90 individuals selected from Ain-shams University Hospitals, Nephrology, Immunology and Rheumatology outpatient clinics or admitted in inpatient wards. Patients were subjected to full clinical examination, disease activity scoring using SLEDAI score and laboratory investigations results were collected including KFTs, ANA, Anti ds DNA, C3, C4, also, results for Histopathological assessment for renal biopsy for LN patients. Serum antificolin-2 antibody titer was measured using ELISA method. The patients were further divided into three groups of 30 each: • Group A: 30 patients SLE with LN as confirmed by recent renal biopsy. • Group B: 30 SLE patients without LN. • Group C: 30 apparently healthy controls of comparable age and sex.